Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia

Authors: Arang Rhie aff001;  Ho-Young Son aff001;  Soo Jung Kwak aff001;  Seungbok Lee aff001;  Dong Young Kim aff005;  Bark-Lynn Lew aff008;  Woo-Young Sim aff008;  Jeong-Sun Seo aff001;  Ohsang Kwon aff005;  Jong-Il Kim aff001;  Seong Jin Jo aff005
Authors place of work: Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul, Korea aff001;  Genome Informatics Section, Computational and Statistical Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America aff002;  Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea aff003;  Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul, Korea aff004;  Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea aff005;  Laboratory of Cutaneous Aging and Hair Research, Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea aff006;  Institute of Human-Environmental Interface Biology, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea aff007;  Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea aff008
Published in the journal: PLoS ONE 14(9)
Category: Research Article
doi: 10.1371/journal.pone.0222533


Dutasteride, a dual inhibitor of both type I and II 5α-reductases, is used to treat male pattern hair loss (MPHL). However, patient response to dutasteride varies in each individual, the cause of which is yet to be identified. To identify genetic variants associated with response to dutasteride treatment for MPHL, a total of 42 men with moderate MPHL who had been treated with dutasteride for 6 months were genotyped and analysed by quantitative linear regression, case-control association tests, and Fisher’s exact test. The synonymous single nucleotide polymorphism (SNP) rs72623193 in DHRS9 was most significantly associated with response to dutasteride, followed by the non-synonymous SNP rs2241057 in CYP26B1. Additionally, variants in ESR1, SRD5A1, CYP19A1, and RXRG are suggested to be associated with response to dutasteride. Cumulative effect and interaction among these SNPs were presented in both additive and non-additive models.


Biology and life sciences – Genetics – Heredity – Genetic mapping – Biochemistry – Physical sciences – Research and analysis methods – Molecular biology – Genetic loci – Molecular genetics – Mathematics – Anatomy – Integumentary system – Skin – Hair follicles – Hair – Medicine and health sciences – Alleles – Pharmacology – Statistics – Mathematical and statistical techniques – Statistical methods – Pharmacokinetics – Drug metabolism – Hormones – Androgens – Regression analysis – Linear regression analysis – Variant genotypes


Male pattern hair loss (MPHL) is an androgen-dependent progressive hair loss caused by shortening of anagen duration leading to miniaturization of involved hair follicles [1, 2]. About 80% of Caucasian men have MPHL by 70 years of age [3]. MPHL develops in genetically predisposed individuals. In a twin study, the heritability was estimated to be over 80% [4]. A polymorphism in the androgen receptor (AR) gene is associated with MPHL [510]. Recently, genome-wide association studies identified several loci associated with MPHL [913]. However, MPHL genetics are still not fully understood.

Androgen is the most important factor in the pathophysiology of MPHL. Although the major circulating androgen is testosterone, the androgen responsible for MPHL is dihydrotestosterone (DHT), which is synthesized from testosterone by 5α-reductase (5AR) in hair follicles and sebaceous glands. Thus, 5AR inhibition is a primary treatment target for MPHL. Varying amounts of hair regrow in MPHL patients treated with finasteride, a selective type II 5AR [14], and dutasteride, a dual inhibitor of both type I and type II 5ARs [15, 16],

However, 5AR inhibition does not always guarantee hair regrowth in the patients with MPHL, and response to medication varies in each individual. In a previous study, about 30% of patients treated with dutasteride for 6 months revealed ‘no global change’ as determined by investigator photographic assessment and subject self-assessment [15, 16]. The cause of the individual difference in response to 5AR inhibition for MPHL has not yet been identified.

In this study, we classified MPHL patients treated with dutasteride for 6 months into good- and poor-response groups according to the degree of hair regrowth and performed association analysis by targeting 154 genes related to the androgen pathway and drug metabolism.

Materials and methods


This study protocol was approved by the Institutional Review Board of Seoul National University Hospital (H-1007-015-322). The target subjects were men with moderate MPHL (IIIv, IV, and V according to the modified Norwood-Hamilton classification scale) who had participated in the previous phase III study to evaluate the efficacy and safety of dutasteride (0.5 mg) [15]. They were treated with dutasteride or a placebo for 6 months. We contacted the 64 subjects who had been assigned to the dutasteride treatment group and had completed the clinical trial, and took peripheral blood samples from them after obtained a written informed consent. Their epidemiological characteristics and hair counts before and after treatment were obtained from the phase III study of dutasteride. To evaluate treatment response, the hair counts were measured at the same circular area marked with ink tatoo before and after 6 months of treatment (S1 Fig); that is, a substantial increase in hair count was considered a good response to dutasteride.

Library construction and targeted sequencing

DNA was extracted from peripheral blood samples of the subjects. Target genes were carefully selected among genes known to be associated with MPHL in previous genetic studies including genome-wide association study and genes related to the steroid hormone biosynthesis (S1 Table) [510, 1719]. In total, 154 genes were targeted (120 for whole gene and 34 for exon only) with the NimbleGen SeqCap EZ Choice Library. We performed sequencing with HiSeq2000 (Illumina, Inc. San Diego, CA, USA).

Variant calling and SNP filtering

We aligned the DNA with the human genome reference sequence (GRCh37) using Bowtie2 [20]. Single nucleotide polymorphisms (SNPs) were called with Genome Analysis Toolkit (GATK, version 2.5) SNPs were filtered as following criteria. (i) SNP candidates were called from a sequencing region with a minimum coverage of 10×, with at least 5× the appearance of a minor allele. (ii) Among these candidate SNPs, only variants with an average quality score of 20 (Phred scale) were chosen. (iii) Allelic frequency (100 × Minor allele counts / Total allele counts) of less than 20% were considered as a sequencing error, 20–80% were considered as a heterozygote, and over 80% were considered as a homozygote [21, 22]. We annotated genetic variants using the software ANNOVAR [23] and called copy number variation using the software CoNIFER [24].

Association test analysis

By setting the phenotype as the change in hair count after the 6-month treatment with dutasteride (0.5 mg), quantitative regression-based association tests between phenotype and genotype were performed for all SNPs, following which quantitative association tests using linear regression were performed for the data generated from all subjects with unadjusted and age adjusted models. Furthermore, we conducted quantitative association tests with good- and poor-response groups as cases and controls, respectively. The case/control association test was conducted twice using 2 different standards for classification: upper half vs. lower half and top quartile vs. bottom quartile response to dutasteride. To enhance confidence in our selected candidates, Fisher’s exact tests were performed on the groups as well. All of the association tests were conducted using PLINK [25]. Multiple test corrections were performed using Bonferroni correction, taking into account linkage disequilibrium (LD) blocks with a threshold of R2 >0.8 using pairwise tagging in HaploView [26].

Gene-based association analysis

Gene-based association tests were conducted using VEGAS [27] 4 times on the statistically significant SNPs, as determined by the 4 prior association tests, with over 105 simulations of each gene. To identify a hidden association, i.e. the cumulative effect among exonic SNPs, one exonic variant was selected from each gene as a tagged SNP. Each SNP with a positive effect was rated as “+1” and with a negative effect as “-1”. Allele frequencies of good- and poor-response groups were compared that of an Asian population.

Multifactor dimension reduction modelling

To evaluate the non-additive effect, Multifactor Dimension Reduction (MDR) [28], a statistical epistasis analysis method for genetic association, was conducted. We used the 6 exonic variation candidates in Fig 1 to perform a multifactor dimensionality reduction analysis using MDR 3.0.2 ( We classified the variations by their haplotypes and considered a poor responder group (class “1”) and a good responder group (class “2”) as discrete variables. Before the analysis, the attribute count range was configured as 1:6 to determine the number of attributes that fit the best model by considering the balancing accuracy and cross-validation consistency using all 6 SNPs.

<h2>Genotypic landscape of 42 patients and the cumulative effect of each allele count and their positive or negative effect.</h2>
Fig. 1.

Genotypic landscape of 42 patients and the cumulative effect of each allele count and their positive or negative effect.

In the upper figure, boxes represent the genotypes of each sample. Light-coloured boxes represent heterozygote SNPs and dark-coloured boxes represent homozygote SNPs. SNPs with negative effects and positive effects, as determined from the regression test, are in the red boxes and blue boxes, respectively. The lower figure shows cumulative effect by counting the number of SNPs. By considering SNPs with a negative effect as -1 and those with a positive effect as +1 as well as by applying regression tests to these cumulative scores, a positive relationship between the cumulative effect of SNPs and the change in hair count was observed. In both figures, samples are ordered along the X-axis from those showing the poorest to the best response in terms of change in hair count.


In total, 42 out of 64 MPHL subjects enrolled in the previous phase III clinical trial that received dutasteride (0.5 mg) for 6 months agreed to participate and were included in this pharmacogenetic study (S2 Table). To evaluate non-genetic factors associated with response to dutasteride, we compared the age, height, and weight and the duration of MPHL between the 10 highest- and 10 lowest-ranked patients based on their hair count increase after 6 months of treatment; however, we did not find any significant differences among the subjects with respect to these parameters (S3 Table).

The outline of the genetic analysis is shown in S2 Fig. Subjects were sequenced with a customized targeted capture kit for next-generation sequencing. On average, 4.3 Gb were sequenced per sample, and 92.37% of the target region was covered over 30×, with a mean depth of coverage 296.3× (S4 Table). Among the 9524 SNPs called, 3430 were left in the target region after removing low quality, homogeneous SNPs, and singletons. From these SNPs, we could identify 86 exonic variants (34 non-synonymous, 49 synonymous, 1 stop-gain, and 2 unknown) and 1 splice-junction variant that affects protein coding. Copy number variation was assessed using CoNIFER [24]. We found 2 deletions in the poor-response group: 1 was found in CYP4Z2P of the poorest responder and the other in CYP2A6 of 2 patients who showed 2nd and 9th poorest responses (S3 Fig). However, because of the small sample size, we could not determine the statistical significance of these deletions.

To identify variants associated with response to dutasteride, we first performed quantitative regression tests on all 42 samples’ genotypes and found 162 candidate variants that were significantly associated with an increase in hair count after dutasteride treatment (S5 Table). Interestingly, ESR1 had 51 variants that were strongly associated with response to dutasteride, all of which are located in the intronic region.

Further, to identify the relevant genetic variants more precisely, we performed a case-control association test by comparing the good- and poor-response groups. We divided subjects into 2 groups based on the increase in hair count after treatment with dutasteride and set the upper half as cases and the lower half as controls. A total of 137 variants were significant with p <0.05, and ESR1 was again determined to be the gene with the most number of significant variants (a total of 40) (S6 Table).

To identify genotypes associated with extreme phenotypes, we performed additional case-control association tests with the top and bottom quartiles of subjects and found 127 variants that were significant (S7 Table). Additionally, Fisher’s exact test on these 2 quartiles showed 53 variants that were more stringently associated with response to dutasteride (S8 Table). In addition to variants in ESR1, a few intronic variants in DHRS9 were highly ranked in these 2 tests.

To identify the functional effects of SNPs, we summarized the exonic variants identified from these 4 association tests (Table 1). Synonymous SNP rs72623193 in the DHRS9 gene was the most significant variant and the only exonic variant that passed all 4 association tests. A linear regression test revealed a negative effect of this SNP on response to dutasteride in (β = -11.70).

Tab. 1.

SNPs in the exonic region that are statistically associated with response to dutasteride.

<h2>SNPs in the exonic region that are statistically associated with response to dutasteride.</h2>

Two missense mutations, rs2241057 in CYP26B1 and rs700519 in CYP19A1, were also associated with response to dutasteride. Rs2241057 showed a negative effect (β = -17.66) and was found only in subjects of the poor-response group with heterozygote genotypes. On the other hand, rs700519 had a positive effect (β = 10.56) with a tendency of increased allelic frequency in good responders. However, these mutations were not predicted to cause a dramatic damage in gene function. PolyPhen2 predicted both mutations as ‘benign,’ whereas SIFT predicted the latter mutation as deleterious.

To determine the gene-level association, we performed gene-based association tests using previously determined significant genotypes of the SNPs described above (Table 2). DHRS9 and ESR1 passed all 4 gene-based association tests. Interestingly, most of the variants in these genes had shared haplotypes (S4A and S4B Fig) and the same type of effect in linear regressions. SNPs in DHRS9 had a negative effect (β ≤ -10.13) compared to SNPs in ESR1 (β ≥ 8.378) (S9 Table). Although they did not pass all of the association tests, RARG, H3F3A, SRD5A1, and HDAC1 are also suggested to have substantial effects on response to dutasteride. SNPs in SRD5A1 showed a positive association with drug response (β ≥ 9.095). An LD plot of these SNPs shows that they are significantly associated (p < 0.05) in a 25-Kb long region of SRD5A1 (S4(C) Fig).

Tab. 2.

Results of the gene-level association tests.

<h2>Results of the gene-level association tests.</h2>

By taking 1 exonic variant from each gene as a tagged SNP, each variant with a positive effect was treated as a protective factor and that with a negative effect was treated as a risk factor. We empirically calculated the cumulative effect by adding allele counts of each SNP and subtracting the risk factors from the protective factors. The regression of the cumulative effect was positively correlated with response to dutasteride (Fig 1). Allele frequencies of each SNP were different between poor and good responders. Asian frequency obtained from the 1000 Genomes Project was in-between allele frequencies of the poor-/good-response groups in all SNPs except for CYP4V2 (S5 Fig).

To examine hidden associations, also called as gene-gene interactions or epistasis, we performed a non-parametric, genetic model-free data mining strategy MDR by using the 6 loci described above. The results of the cross-validation statistics used for training and testing the MDR model and the predicted class of each genotype combination were shown in S10 and S11 Tables. For a detailed model description of values in entropy-based measures for information gain (IG) and interaction (I), see S12 and S13 Tables. For equations used to calculate IG and I [28]. This model had cross-validation consistency of 10 with a balanced accuracy of 87.19% (Fig 2 and S10S13 Tables). Polymorphisms in CYP19A1 and DHRS9 synergistically interact (i.e. non-additive or exclusive-OR interactions) and had the most entropy (3.77%), followed by CYP26B1 and CYP4V2 (3.19%). DHRS9 and CYP26B1 are highly additive (redundancy or lack of information gain, -7.35%). This result indicates existence of nonlinear interactions between SNPs that underlie the cumulative effect.

<h2>Entropy-based interaction graph for exonic variations drawn with Multifactor Dimension Reduction (MDR) analysis of good-/-poor responders treated as cases/controls.</h2>
Fig. 2.

Entropy-based interaction graph for exonic variations drawn with Multifactor Dimension Reduction (MDR) analysis of good-/-poor responders treated as cases/controls.

Positive entropy indicates information gain or synergistic effect (i.e. non-additive), whereas negative entropy indicates redundancy or lack of information gain. Model statistics as well as single and pairwise attribute values for information gain and interactions are listed in S10S13 Tables.


Dutasteride is a dual inhibitor of type I and II 5ARs and has proven to be an effective and tolerable treatment modality for MPHL. It improves hair growth in a dose-dependent manner by reduction of serum and scalp DHT [16]. The response to dutasteride varies in each individual, but genetic factors related to individual differences are unclear. In this study, we found several candidate regions associated with response to dutasteride in MPHL treatment through genotypic association tests.

In our study, the most significant exonic variant was rs72623193 located in DHRS9, that was ranked the highest in the gene-based tests. DHRS9 (dehydrogenase/reductase SDR family member 9) has been identified as a 3α-hydroxysteroid dehydrogenase (3α-HSD) [29]. It is a microsomal enzyme whereas other 3α-HSDs in the aldoketoreductase gene superfamily (AKR1C1–AKR1C4) are cytosolic enzymes. This enzyme is expressed in the human epidermis, hair follicles, and sebaceous glands [30, 31]. Since DHRS9 is involved in the synthesis of DHT from 3α-androstanediol [29], upregulation would facilitate the backdoor pathway to DHT in the scalp tissue even when 5AR is inhibited by dutasteride (S6(A) Fig). A previous study showed that there was negative correlation between the change in hair count and the percent change of scalp DHT after treatment with the 5AR inhibitor [16].

Additionally, DHRS9 possesses retinol dehydrogenase (RolDH) activity [32, 33], which converts retinol to retinal in retinoid acid (RA) synthesis (S6(B) Fig). Because DHRS9 can oxidize retinol that is bound to the cellular retinol-binding protein while many other RolDHs cannot [34, 35], it is regarded as a physiological enzyme [35]. Its expression changes during hair cycling in mice and increases in hair follicles of C57BL/6J mice that frequently develop dorsal skin alopecia. DHRS9 also increased in the hair follicles of patients with central centrifugal cicatricial alopecia [30]. Previous studies demonstrated that RA synthesis and the RA signalling system are related to hair growth and cycling [35, 36]. Furthermore, RA was reported to regulate bone morphogenetic protein and Wnt signalling pathways, which are involved in hair growth [37].

Rs2241057, the second most significant exonic SNP in this study, is located on CYP26B1, which is also involved in regulation of RA level. RA is metabolized by cytochrome P450 26 family members (CYP26A1, B1, and C1) (S6(B) Fig) [38]. CYP26A1 and CYP26B1 are expressed and are RA-inducible in both reconstructed and in vivo human epidermis [39, 40], but CYP26B1 was suggested to be more effective under physiological conditions [41], CYP26B1 is able to inactivate both all-trans-RA and 9-cis-RA [42]. Additionally, we found that rs1128977 on RXRG is associated with response to dutasteride. This gene encodes retinoid X receptor-γ (RXRG), a nuclear receptor that is activated by 9-cis-RA. Taken together, these findings strongly suggest that RA metabolism and the RA signalling pathway are associated with response to dutasteride in MPHL, although mechanism of action needs to be elucidated in future studies.

We also found that response to dutasteride may be associated with variants of genes involved in steroid hormone metabolism, such as SRD5A1, ESR1, and CYP19A1 (S6(A) Fig). The product of SRD5A1 is type I 5AR, which is a target of dutasteride. Dutasteride inhibits both type I and II 5ARs, while finasteride selectively inhibits type II 5AR. Therefore, a variation in SRD5A1 might affect the subject’s response to dutasteride during treatment for MPHL. However, SRD5A2 encoding type II 5AR was not associated with response to dutasteride.

In addition to androgens, it has long been known that oestrogen also effects hair follicle growth by binding locally expressed oestrogen receptors (ERs) [43]. ESR1 encodes ERα, which is 1 of 2 distinct isoforms of ERs. CYP19A1 converts androstenedione to estrone (E1) and testosterone to 17β-estradiol (E2). It has been reported that ERα is maximally expressed during telogen, and E2 inhibits hair growth [44, 45]. Moreover, E2 modifies androgen metabolism in pilosebaceous units [43].

In this study, no individual variant passed the filtering criteria after multiple tests correction was applied. This might be due to the small number of participants enrolled in this study. However, we cannot exclude the effects of interaction between multiple variants, considering that MPHL is very complex, and the hair-count change in each patient after treatment was distributed continuously and was not clearly divided into different groups. We hypothesize that the individual difference in response to dutasteride comes from the cumulative effects of multiple variants rather than that of a single responsible variant and depicts a genotypic landscape with good correlation between the allele frequency scores of the tagged exonic SNPs and response to dutasteride. Results from MDR analysis are also consistent with the existence of an interaction between SNPs. Therefore, we propose that these SNPs, when used simultaneously, could be suitable markers for clinicians to predict response to dutasteride in patients with MPHL.

In conclusion, we identified candidate variants associated with response to dutasteride for MPHL. According to the association tests, potential candidate variants are located on DHRS9, CYP26B1, ESR1, SRD5A1, CYP19A1, and RXRG. These genes encode proteins involved in the backdoor pathway of DHT synthesis, RA metabolism and the RA signalling pathway, and steroid hormone metabolism. To the best of our knowledge, this study is the first to show genetic variation associated with drug response in patients with MPHL. Moreover, this study could be developed further to investigate the cumulative effect of multiple variants. Our findings would contribute to the investigation on the pathophysiology of MPHL and can potentially help clinicians improve treatment of MPHL patients by using 5AR inhibitors.

Supporting information

S1 Table [xlsx]
List of the target genes.

S2 Table [xlsx]
Epidemiologic data of the individual subjects.

S3 Table [xlsx]
Epidemiological characteristics of the enrolled subjects with MPHL who had been treated with dutasteride (0.5 mg) for 6 months.

S4 Table [xlsx]
Sequencing summary of 42 subjects.

S5 Table [xlsx]
List of SNPs from quantitative linear regression test under p-value < 0.05.

S6 Table [xlsx]
List of SNPs from upper half (n = 21) and lower half (n = 21) case-control association test under p-value < 0.05.

S7 Table [xlsx]
List of SNPs from extreme phenotypes (n = 10 on each) case-control association test under p-value < 0.05.

S8 Table [xlsx]
List of SNPs from extreme phenotypes (n = 10 on each) case-control Fisher's exact test under p-value <0.05.

S9 Table [xlsx]
Genes and the number of SNPs commonly and significantly associated (p <0.05) with response to dutasteride as determined by 4 association tests.

S10 Table [xlsx]
Results of the cross-validation statistics used for training and testing the MDR model with the 6 genotyped exonic SNPs.

S11 Table [xlsx]
Predicted class of each genotype combination.

S12 Table [xlsx]
Single attribute values in entropy-based measures for information gain and interaction depicted in .

S13 Table [xlsx]
Pairwise attribute values in entropy-based measures for information gain and interaction depicted in .

S1 Fig [png]
Representative phototrichogram for the measurement of hair counts.

S2 Fig [tif]
Schematic representation of SNP calling, variant filtering steps, and statistical analysis workflow.

S3 Fig [a]
Copy number variations found in the poor-response group.

S4 Fig [a]
Linkage disequilibrium (LD) blocks of variants in genes associated with drug response in MPHL treatment.

S5 Fig [pdf]
Comparison of the allele frequency of each group as determined by the present study with the Asian allele frequency obtained from the 1000 Genomes Project.

S6 Fig [a]
Overview of metabolic pathways of steroids and reitnoids.


1. Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998;317(7162):865–9. doi: 10.1136/bmj.317.7162.865 9748188; PubMed Central PMCID: PMC1113949.

2. Whiting DA. Male pattern hair loss: current understanding. Int J Dermatol. 1998;37(8):561–6. doi: 10.1046/j.1365-4362.1998.00542.x 9731996

3. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359–65. doi: 10.1097/00007611-197511000-00009 1188424.

4. Nyholt DR, Gillespie NA, Heath AC, Martin NG. Genetic basis of male pattern baldness. J Invest Dermatol. 2003;121(6):1561–4. doi: 10.1111/j.1523-1747.2003.12615.x 14675213

5. Ellis JA, Stebbing M, Harrap SB. Polymorphism of the androgen receptor gene is associated with male pattern baldness. J Invest Dermatol. 2001;116(3):452–5. doi: 10.1046/j.1523-1747.2001.01261.x WOS:000167222200014. 11231320

6. Hayes VM, Severi G, Eggleton SA, Padilla EJD, Southey MC, Sutherland RL, et al. The E211 G > A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidem Biomar. 2005;14(4):993–6. doi: 10.1158/1055-9965.Epi-04-0778 WOS:000228351300038. 15824176

7. Hillmer AM, Hanneken S, Ritzmann S, Becker T, Freudenberg J, Brockschmidt FF, et al. Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet. 2005;77(1):140–8. doi: 10.1086/431425 15902657

8. Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E. Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005;15(5):339–40. WOS:000232392300005. 16172040

9. Richards JB, Yuan X, Geller F, Waterworth D, Bataille V, Glass D, et al. Male-pattern baldness susceptibility locus at 20p11. Nat Genet. 2008;40(11):1282–4. doi: 10.1038/ng.255 WOS:000260501500017. 18849991

10. Hillmer AM, Flaquer A, Hanneken S, Eigelshoven S, Kortum AK, Brockschmidt FF, et al. Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26. Am J Hum Genet. 2008;82(3):737–43. doi: 10.1016/j.ajhg.2007.11.014 18304493; PubMed Central PMCID: PMC2427264.

11. Li R, Brockschmidt FF, Kiefer AK, Stefansson H, Nyholt DR, Song K, et al. Six novel susceptibility Loci for early-onset androgenetic alopecia and their unexpected association with common diseases. PLoS Genet. 2012;8(5):e1002746. Epub 2012/06/14. doi: 10.1371/journal.pgen.1002746 22693459; PubMed Central PMCID: PMC3364959.

12. Heilmann S, Kiefer AK, Fricker N, Drichel D, Hillmer AM, Herold C, et al. Androgenetic alopecia: identification of four genetic risk loci and evidence for the contribution of WNT signaling to its etiology. J Invest Dermatol. 2013;133(6):1489–96. Epub 2013/01/30. doi: 10.1038/jid.2013.43 23358095.

13. Brockschmidt FF, Heilmann S, Ellis JA, Eigelshoven S, Hanneken S, Herold C, et al. Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness. Br. 2011;165(6):1293–302. Epub 2011/10/29. doi: 10.1111/j.1365-2133.2011.10708.x 22032556.

14. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4):578–89.

15. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–8. doi: 10.1016/j.jaad.2009.09.018 WOS:000280252100008. 20605255

16. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–23. doi: 10.1016/j.jaad.2006.05.007 17110217

17. Prodi DA, Pirastu N, Maninchedda G, Sassu A, Picciau A, Palmas MA, et al. EDA2R is associated with androgenetic alopecia. J Invest Dermatol. 2008;128(9):2268–70. doi: 10.1038/jid.2008.60 18385763

18. Hillmer AM, Freudenberg J, Myles S, Herms S, Tang K, Hughes DA, et al. Recent positive selection of a human androgen receptor/ectodysplasin A2 receptor haplotype and its relationship to male pattern baldness. Hum Genet. 2009;126(2):255–64. doi: 10.1007/s00439-009-0668-z 19373488

19. Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, Southey MC, et al. 5α−Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer. 2007;120(4):776–80. doi: 10.1002/ijc.22408 17136762

20. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9. doi: 10.1038/nmeth.1923 22388286; PubMed Central PMCID: PMC3322381.

21. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303. doi: 10.1101/gr.107524.110 20644199; PubMed Central PMCID: PMC2928508.

22. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8. doi: 10.1038/ng.806 WOS:000289972600023. 21478889

23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164–e. doi: 10.1093/nar/gkq603 20601685

24. Krumm N, Sudmant PH, Ko A, O'Roak BJ, Malig M, Coe BP, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012;22(8):1525–32. doi: 10.1101/gr.138115.112 22585873; PubMed Central PMCID: PMC3409265.

25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. doi: 10.1086/519795 17701901; PubMed Central PMCID: PMC1950838.

26. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5. doi: 10.1093/bioinformatics/bth457 15297300.

27. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A versatile gene-based test for genome-wide association studies. Am J Hum Genet. 2010;87(1):139–45. doi: 10.1016/j.ajhg.2010.06.009 20598278; PubMed Central PMCID: PMC2896770.

28. Moore JH, Gilbert JC, Tsai CT, Chiang FT, Holden T, Barney N, et al. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol. 2006;241(2):252–61. doi: 10.1016/j.jtbi.2005.11.036 16457852.

29. Chetyrkin SV, Belyaeva OV, Gough WH, Kedishvili NY. Characterization of a Novel Type of Human Microsomal 3α-Hydroxysteroid Dehydrogenase. J Biol Chem. 2001;276(25):22278–86. doi: 10.1074/jbc.M102076200 11294878

30. Everts HB, Silva KA, Montgomery S, Suo L, Menser M, Valet AS, et al. Retinoid metabolism is altered in human and mouse cicatricial alopecia. J Invest Dermatol. 2013;133(2):325–33. doi: 10.1038/jid.2012.393 23096705; PubMed Central PMCID: PMC3546159.

31. Markova NG, Pinkas-Sarafova A, Karaman-Jurukovska N, Jurukovski V, Simon M. Expression pattern and biochemical characteristics of a major epidermal retinol dehydrogenase. Mol Genet Metab. 2003;78(2):119–35. 12618084.

32. Rexer BN, Ong DE. A novel short-chain alcohol dehydrogenase from rats with retinol dehydrogenase activity, cyclically expressed in uterine epithelium. Biol Reprod. 2002;67(5):1555–64. doi: 10.1095/biolreprod.102.007021 12390888.

33. Soref CM, Di Y-P, Hayden L, Zhao YH, Satre MA, Wu R. Characterization of a novel airway epithelial cell-specific short chain alcohol dehydrogenase/reductase gene whose expression is up-regulated by retinoids and is involved in the metabolism of retinol. J Biol Chem. 2001;276(26):24194–202. doi: 10.1074/jbc.M100332200 11304534

34. Napoli JL. Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim Biophys Acta. 1999;1440(2):139–62.

35. Everts HB, Sundberg JP, King LE Jr., Ong DE. Immunolocalization of enzymes, binding proteins, and receptors sufficient for retinoic acid synthesis and signaling during the hair cycle. J Invest Dermatol. 2007;127(7):1593–604. doi: 10.1038/sj.jid.5700753 17363914.

36. Everts HB, King LE Jr., Sundberg JP, Ong DE. Hair cycle-specific immunolocalization of retinoic acid synthesizing enzymes Aldh1a2 and Aldh1a3 indicate complex regulation. J Invest Dermatol. 2004;123(2):258–63. doi: 10.1111/j.0022-202X.2004.23223.x 15245423.

37. Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res. 2002;43(11):1773–808. doi: 10.1194/jlr.r100015-jlr200 12401878.

38. Roos TC, Jugert FK, Merk HF, Bickers DR. Retinoid metabolism in the skin. Pharmacol Rev. 1998;50(2):315–33. 9647871.

39. Loriè EP, Chamcheu JC, Vahlquist A, Törmä H. Both all-trans retinoic acid and cytochrome P450 (CYP26) inhibitors affect the expression of vitamin A metabolizing enzymes and retinoid biomarkers in organotypic epidermis. Arch Dermatol Res. 2009;301(7):475–85. doi: 10.1007/s00403-009-0937-7 19294396

40. Pavez Lorie E, Cools M, Borgers M, Wouters L, Shroot B, Hagforsen E, et al. Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. Br. 2009;160(1):26–36. doi: 10.1111/j.1365-2133.2008.08895.x 19016711.

41. Pavez Lorie E, Li H, Vahlquist A, Torma H. The involvement of cytochrome p450 (CYP) 26 in the retinoic acid metabolism of human epidermal keratinocytes. Biochim Biophys Acta. 2009;1791(3):220–8. Epub 2009/01/28. doi: 10.1016/j.bbalip.2008.12.004 19171200.

42. White JA, Ramshaw H, Taimi M, Stangle W, Zhang AQ, Everingham S, et al. Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism. P Natl Acad Sci USA. 2000;97(12):6403–8. doi: 10.1073/pnas.120161397 WOS:000087526300033. 10823918

43. Ohnemus U, Uenalan M, Inzunza J, Gustafsson JÅ, Paus R. The hair follicle as an estrogen target and source. Endocr Rev. 2006;27(6):677–706. doi: 10.1210/er.2006-0020 16877675

44. Oh H-S, Smart RC. An estrogen receptor pathway regulates the telogen-anagen hair follicle transition and influences epidermal cell proliferation. P Natl Acad Sci USA. 1996;93(22):12525–30.

45. Ohnemus U, Unalan M, Handjiski B, Paus R. Topical estrogen accelerates hair regrowth in mice after chemotherapy-induced alopecia by favoring the dystrophic catagen response pathway to damage. J Invest Dermatol. 2004;122(1):7–13. doi: 10.1046/j.0022-202X.2003.22120.x 14962083.

Článok vyšiel v časopise


2019 Číslo 9